Core Viewpoint - Innovent Biologics has been successfully included as a constituent stock of the Hang Seng Index (HSI), marking a significant milestone in its development and recognition in the international capital market [1][4][5]. Company Overview - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on developing high-quality medicines for major diseases such as cancer, cardiovascular and metabolic disorders, autoimmune diseases, and ophthalmology [3][6]. - The company has launched 16 products and has a diversified drug pipeline that includes monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and small-molecule drugs [3][6]. Market Recognition - The inclusion in the HSI and other indices like the Hang Seng China Enterprises Index (HSCEI) and the Hang Seng ESG Enhanced Index highlights the strong recognition of Innovent's value as an innovative biopharmaceutical company [1][4]. - This milestone reflects the Hong Kong stock market's preference for high-quality Chinese innovative biopharmaceutical enterprises [4]. Strategic Implications - Innovent's inclusion in the HSI is expected to broaden its investor base, enhance international visibility, and provide solid capital support for ongoing investments in innovative R&D and global business expansion [5]. - The company aims to continue its mission of developing affordable, high-quality biopharmaceuticals for patients worldwide, thereby creating long-term value for investors [5][6].